RYTM stock forecast, quote, news & analysis
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases... Show more
Why Rhythm Pharmaceuticals (RYTM) Stock Is Up +22.6% in the Last 30 Days
Key Takeaways
- Rhythm Pharmaceuticals (RYTM) shares surged approximately 22.6% over the last 30 days, climbing from $89.70 on June 15 to $109.96 as of July 14, 2026.
- Multiple positive clinical data presentations at ENDO 2026, including promising six-month Phase 2 results for setmelanotide in Prader-Willi syndrome and 52-week bivamelagon data, fueled investor enthusiasm.
- Several Wall Street analysts reiterated bullish ratings and raised price targets, with Citizens and Canaccord Genuity setting targets as high as $151–$155.
- The Imcivree launch for acquired hypothalamic obesity continues to show strong early momentum, with over 150 patient start forms from 110 unique prescribers in the first six weeks.
- Quarterly performance reflects a broader uptrend driven by regulatory wins, revenue growth, and pipeline expansion across the company's MC4R franchise.
Rhythm Pharmaceuticals (RYTM) Company Overview and Market Position
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in therapies for rare genetic disorders of obesity caused by disruptions in the melanocortin-4 receptor (MC4R) pathway. The company's flagship product, Imcivree (setmelanotide), is a first-in-class MC4R agonist approved for multiple indications, including Bardet-Biedl syndrome (BBS), POMC and LEPR deficiency obesities, and most recently, acquired hypothalamic obesity (HO). Rhythm also advances a pipeline of next-generation MC4R candidates, including oral bivamelagon and weekly injectable RM-718, designed to expand the therapeutic franchise and improve patient convenience. With a global commercial presence spanning more than 25 countries, Rhythm combines rare-disease drug development with specialized commercial execution, making it a closely followed name in the biotech space.
Rhythm Pharmaceuticals (RYTM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, RYTM shares delivered a sharp rally, gaining approximately 22.6% from a closing price of $89.70 on June 15, 2026, to $109.96 on July 14, 2026. The move accelerated in mid-June following a wave of clinical data releases from the Endocrine Society's ENDO 2026 annual meeting, pushing the stock from the high $80s through the $100 barrier within a single week. The rally extended through late June and into July, with shares reaching as high as $115.48 on July 9 before a modest pullback.
Zooming out to the last quarter, the stock has been on a sustained uptrend. RYTM traded near $85–$88 in early May following its Q1 2026 earnings report, which exceeded consensus estimates with revenue of $60.1 million (+59% year-over-year) and a narrower-than-expected loss. Key catalysts over the quarter included FDA approval of Imcivree for acquired hypothalamic obesity in March, European Commission marketing authorization in early May, and the subsequent commercial launch. The combination of regulatory milestones, encouraging launch metrics, and pipeline progress has defined a multi-month upward trajectory for the stock.
What Drove RYTM Stock Price in the Last 30 Days
The primary catalyst behind RYTM's 30-day surge was the presentation of multiple datasets at ENDO 2026 in mid-June. On June 13, Rhythm announced positive interim six-month Phase 2 data for setmelanotide in Prader-Willi syndrome, with 17 of 18 patients remaining on therapy and demonstrating improvements in BMI, body composition, and hyperphagia scores. This opened a potential new multi-billion-dollar indication for the drug. Separately, 52-week data for oral bivamelagon showed BMI reductions of approximately 11–17%, comparable to setmelanotide's efficacy but with lower hyperpigmentation and convenient daily oral dosing, strengthening the long-term pipeline narrative.
Analyst activity amplified the momentum. On June 16, Citizens reiterated its Market Outperform rating and $155 price target following the bivamelagon data. Canaccord Genuity raised its target to $151, while Stifel and TD Cowen maintained Buy ratings at $133 and $130, respectively. On July 14, Citizens again reaffirmed its bullish stance after an endocrinologist survey indicated Imcivree is outperforming in the HO launch, with the firm raising Q2 sales estimates. Institutional accumulation also contributed: filings showed Pictet Asset Management increased its RYTM stake by 8.5% in Q1, and multiple other funds added positions.
What Drove RYTM Stock Performance Over the Last Quarter
The quarterly performance story is anchored in Rhythm's successful transition from a single-indication rare-disease company to a multi-indication commercial franchise. The FDA approval of Imcivree for acquired hypothalamic obesity on March 19, 2026, expanded the U.S. addressable patient population by an estimated 10,000 patients. The company rapidly scaled its sales force from 16 to 42 territory managers and reported 150 patient start forms within six weeks of launch—signaling robust early demand. Q1 2026 revenue of $60.1 million reflected 59% year-over-year growth, with international markets contributing 39% of sales and growing 27% sequentially. The European Commission's marketing authorization in early May further de-risked the global commercial thesis, while Japan's regulatory review remains on track for a potential year-end launch. Combined with pipeline progress on bivamelagon, RM-718, and Prader-Willi syndrome, the quarter built a compelling case for Rhythm's expanding MC4R franchise.
Trending AI Robots
For investors seeking data-driven insights beyond individual stock analysis, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron operates hundreds of AI-driven trading bots across thousands of tickers, but only the most relevant and consistently high-performing bots are featured in this section. These bots employ diverse strategies, timeframes, and performance metrics—ranging from short-term technical pattern recognition to longer-term momentum and valuation-based approaches. The page is designed to help traders and investors quickly identify AI trading tools that align with their own market outlook and risk preferences. Exploring the Trending AI Robots section can provide a valuable complement to traditional fundamental research.
RYTM Stock Forecast Drivers: What Investors Should Watch Next
Rhythm's Q2 2026 earnings report, expected around August 4, will be the next major catalyst. Investors will scrutinize Imcivree revenue growth, particularly any early signals on HO launch trajectory and payer policy establishment. Full six-month Phase 2 Prader-Willi data—already previewed at ENDO—may receive further elaboration, and any updates on Phase 3 trial design will be closely monitored. The advancement of RM-718 and bivamelagon toward pivotal trials represents another key value driver. On the regulatory front, Japan's PMDA review process and European launch preparations for 2027 remain significant milestones. Risks include ongoing operating losses, high cash burn, and the inherent uncertainty of clinical trial outcomes, particularly in complex indications like Prader-Willi syndrome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RYTM's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for RYTM moved out of overbought territory on July 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where RYTM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RYTM as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RYTM turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RYTM broke above its upper Bollinger Band on June 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
RYTM moved above its 50-day moving average on June 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on June 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 224 cases where RYTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (59.172) is normal, around the industry mean (20.985). P/E Ratio (0.000) is within average values for comparable stocks, (37.521). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). RYTM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (32.362) is also within normal values, averaging (422.678).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of peptide therapeutics for metabolic diseases
Industry Biotechnology